Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do gender differences in CD4 cell counts matter?

M Prins1, J R Robertson, R P Brettle

  • 1Municipal Health Service, Division of Public Health and Environment, Amsterdam, The Netherlands.

AIDS (London, England)
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased risk of non-fatal overdose associated with non-prescribed benzodiazepine use in Scotland, UK.

The International journal on drug policy·2023
Same author

MR elastography-based staging of liver fibrosis in Fontan procedure associated liver disease is confounded by effects of venous congestion.

Clinical radiology·2022
Same author

Liver function tests in primary care provide a key opportunity to diagnose and engage patients with hepatitis C.

Epidemiology and infection·2022
Same author

From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic.

The International journal on drug policy·2021
Same author

National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey.

Public health·2021
Same author

National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.

Public health·2021
Same journal

Hazardous alcohol use, sexual behavior, and recent and undiagnosed HIV across 11 Eastern and Southern African countries.

AIDS (London, England)·2026
Same journal

Carotid inflammation on FDG-PET is associated with lower cognitive performance in people with treated HIV infection.

AIDS (London, England)·2026
Same journal

Clinical implications of the new definition of obesity among persons with HIV.

AIDS (London, England)·2026
Same journal

Cabotegravir and rilpivirine resistance-associated mutations among people with newly diagnosed HIV-1 in the Netherlands.

AIDS (London, England)·2026
Same journal

Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVE.

AIDS (London, England)·2026
Same journal

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
See all related articles

Women with HIV experience slower disease progression and maintain higher CD4 counts than men, suggesting a potential delay in initiating highly active antiretroviral therapy (HAART) for women.

Area of Science:

  • Immunology
  • Virology
  • Epidemiology

Background:

  • Gender influences disease progression and CD4 lymphocyte counts in HIV infection.
  • Understanding these differences is crucial for effective treatment strategies.

Purpose of the Study:

  • To investigate the impact of gender on HIV disease progression.
  • To determine if gender-based differences in CD4 lymphocyte counts persist throughout the course of HIV infection.

Main Methods:

  • Longitudinal modeling of CD4 lymphocyte counts in 221 female and 443 male HIV seroconverters.
  • Regression analysis for repeated measurements, analyzing data backward from AIDS onset and death.

Main Results:

  • Women showed marginally slower progression to AIDS and death before highly active antiretroviral therapy (HAART).

Related Experiment Videos

  • Women maintained higher CD4 counts at seroconversion, AIDS onset, and death compared to men.
  • CD4 count decline rates were similar, except for a steeper decline in men closer to AIDS.

    • Conclusions:

    • Gender differences in CD4 counts may indicate a delayed initiation of HAART in women, potentially by 12 months.
    • Revised treatment guidelines may be necessary to ensure women benefit equally from HAART.